[go: up one dir, main page]

UY28737A1 - Compuestos farmacéuticamente activos - Google Patents

Compuestos farmacéuticamente activos

Info

Publication number
UY28737A1
UY28737A1 UY28737A UY28737A UY28737A1 UY 28737 A1 UY28737 A1 UY 28737A1 UY 28737 A UY28737 A UY 28737A UY 28737 A UY28737 A UY 28737A UY 28737 A1 UY28737 A1 UY 28737A1
Authority
UY
Uruguay
Prior art keywords
active compounds
pharmaceutically active
processes
medicine
class
Prior art date
Application number
UY28737A
Other languages
English (en)
Inventor
David Hepworth
Andrew Antony Calabrese
David Sebastien Fradet
Mark Lansdell
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34864830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28737(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0412417A external-priority patent/GB0412417D0/en
Priority claimed from GB0425530A external-priority patent/GB0425530D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of UY28737A1 publication Critical patent/UY28737A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

La presente invención se refiere a una clase de agonistas de melanocortina CR4 de fórmula general (I) en la que R1, R2, R3, R4 y R5 son como se han definido anteriormente y especialmente a compuestos agonista selectivos de MCR4, a su uso en medicina, a composiciones que los contienen, a procesos para su preparación y a intermedios usados en tales procesos.
UY28737A 2004-02-04 2005-02-03 Compuestos farmacéuticamente activos UY28737A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0402492.3A GB0402492D0 (en) 2004-02-04 2004-02-04 Pharmaceutically active compounds
GB0412417A GB0412417D0 (en) 2004-06-03 2004-06-03 Pharmaceutically active compounds
GB0425530A GB0425530D0 (en) 2004-11-19 2004-11-19 Pharmaceutically active compounds

Publications (1)

Publication Number Publication Date
UY28737A1 true UY28737A1 (es) 2005-09-30

Family

ID=34864830

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28737A UY28737A1 (es) 2004-02-04 2005-02-03 Compuestos farmacéuticamente activos

Country Status (25)

Country Link
EP (1) EP1716135B1 (es)
JP (1) JP4031814B2 (es)
KR (1) KR100830763B1 (es)
CN (1) CN1930146A (es)
AP (1) AP2006003699A0 (es)
AR (1) AR048232A1 (es)
AT (1) ATE511507T1 (es)
AU (1) AU2005213538A1 (es)
BR (1) BRPI0507435A (es)
CA (1) CA2555800C (es)
CR (1) CR8545A (es)
EA (1) EA011159B1 (es)
EC (1) ECSP066751A (es)
GB (1) GB0402492D0 (es)
GE (1) GEP20084361B (es)
IL (1) IL177004A0 (es)
MA (1) MA28348A1 (es)
NL (1) NL1028193C2 (es)
NO (1) NO20063944L (es)
PA (1) PA8623101A1 (es)
PE (1) PE20050772A1 (es)
TW (1) TWI300066B (es)
UY (1) UY28737A1 (es)
WO (1) WO2005077935A1 (es)
ZA (1) ZA200606236B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617654A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
KR20080048502A (ko) * 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
CA2625877A1 (en) * 2005-10-18 2007-04-26 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
AU2007219236B2 (en) 2006-02-23 2012-06-21 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
JP5243274B2 (ja) * 2006-02-23 2013-07-24 ファイザー・リミテッド ４型メラノコルチン受容体アゴニストのピペリジノイルピロリジン
KR20100049644A (ko) 2007-08-07 2010-05-12 다케다 야쿠힌 고교 가부시키가이샤 안드로겐 수용체 조절제로서의 피롤리딘-2-온 유도체
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
US9981960B2 (en) 2014-05-29 2018-05-29 Mitsubishi Tanabe Pharma Corporation Pyrrolidine compound and application as melanocortin receptor agonist
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
US10301286B2 (en) * 2015-08-04 2019-05-28 Astellas Pharma Inc. Piperazine derivative
CN112694436B (zh) * 2020-12-30 2022-07-08 济南周行医药科技有限公司 一种槟榔碱的合成方法
EP4317150A4 (en) * 2021-05-06 2024-10-30 Lg Chem, Ltd. CRYSTAL FORM VII OF A MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR THE PREPARATION THEREOF
CN114211258B (zh) * 2021-11-04 2023-09-26 江阴市大久金属科技有限公司 高精密无缝钢管制备工艺

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2439152C (en) * 2001-02-28 2008-06-17 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
ES2272703T3 (es) * 2001-02-28 2007-05-01 MERCK & CO., INC. Derivados de piperidina acilados como agonistas de receptor de melanocortina-4.

Also Published As

Publication number Publication date
BRPI0507435A (pt) 2007-07-03
CN1930146A (zh) 2007-03-14
PE20050772A1 (es) 2005-10-31
NL1028193C2 (nl) 2006-04-20
AU2005213538A1 (en) 2005-08-25
PA8623101A1 (es) 2006-05-16
ZA200606236B (en) 2008-04-30
ATE511507T1 (de) 2011-06-15
IL177004A0 (en) 2006-12-10
CA2555800C (en) 2010-06-15
WO2005077935A1 (en) 2005-08-25
GB0402492D0 (en) 2004-03-10
MA28348A1 (fr) 2006-12-01
TW200526625A (en) 2005-08-16
TWI300066B (en) 2008-08-21
CR8545A (es) 2007-09-03
EA011159B1 (ru) 2009-02-27
CA2555800A1 (en) 2005-08-25
JP4031814B2 (ja) 2008-01-09
JP2007534668A (ja) 2007-11-29
EA200601279A1 (ru) 2006-12-29
EP1716135B1 (en) 2011-06-01
AP2006003699A0 (en) 2006-08-31
NO20063944L (no) 2006-10-31
EP1716135A1 (en) 2006-11-02
KR100830763B1 (ko) 2008-05-19
NL1028193A1 (nl) 2005-08-08
AR048232A1 (es) 2006-04-12
GEP20084361B (en) 2008-04-29
ECSP066751A (es) 2006-11-16
KR20060127125A (ko) 2006-12-11

Similar Documents

Publication Publication Date Title
UY28737A1 (es) Compuestos farmacéuticamente activos
HN2010001059A (es) Nuevo titulo modificado: compuestos derivados de pirimidina, un proceso para la preparacion de los mismos, una composicion farmaceutica que los comprenden y combinaciones de dichos compuestos con otros agentes.
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
NI201000209A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato
ECSP066541A (es) Nuevos derivados de piridazin-3(2h)-ona
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
UY29267A1 (es) Derivados de piperidina y su uso como agentes antiinflamatorios
ECSP10010693A (es) Compuestos pirazólicos 436
BRPI0913457A2 (pt) "composto, composição farmacêutica, e, uso do composto"
UY29002A1 (es) Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia
UY29058A1 (es) Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato
ECSP11011439A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
ECSP088584A (es) Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl)
UY30610A1 (es) Moduladores de mglur5
AR060536A1 (es) Agonista del receptor de glucocorticoides y composiciones farmaceuticas
UY30808A1 (es) Derivados de benzotiazolonas, composiciones conteniéndolos y aplicaciones
ECSP088265A (es) Derivados de carboxamida como antagonistas del receptor muscarínico
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
ECSP099425A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2
UY29234A1 (es) Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones.
ECSP088603A (es) Nuevas n-(fluor-pirazinil)-fenilsulfonamidas como moduladores del receptor de quimioquina ccr4
CY1113279T1 (el) Φαρμακευτικη συνθεση 271
UY30801A1 (es) Compuestos calciliticos
NI201100015A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico.
UY29003A1 (es) Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160419